Zealand to present at two international healthcare investor conferences in June 2017

Ein Stethoskop auf einem Schreibtisch mit Unterlagen. (Symbolfoto) © SARINYAPINNGAM / iStock / Getty Images Plus / Getty Images http://www.gettyimages.de

Press Release - No. 4 / 2017

Zealand to present at two international healthcare investor conferences in June 2017

Copenhagen, June 2, 2017 - Zealand announces that its President and CEO, Britt Meelby Jensen, and Executive Vice President and CFO, Mats Blom, will present the Company and host investor meetings at the following healthcare investor forums taking place in New York and London in June 2017.

Jefferies 2017 Healthcare Conference, New York - June 6-7, 2017
Zealand Pharma A/S is presenting on: Tue, Jun 6 at 4:30-4:55 PM in 5 Ballroom (breakout at 5:00 PM-05:25 PM in Alvin Room). Britt Meelby Jensen, President and CEO and Mats Blom, Executive Vice President and CFO, will represent the Company.

Citi 2016 Global Healthcare Conference, London - June 21, 2017
Zealand will host one-on-one investor meetings. Britt Meelby Jensen, President and CEO will represent the Company.
Please note that no new financial or other material information relating to Zealand and its business will be disclosed at these meetings.

For further information, please contact:

Britt Meelby Jensen, President and CEO
Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com

Mats Blom, Executive Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.
2
Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin^® in the U.S. and as Lyxumia^® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus^®) and is marketed as Soliqua^® 100/33 in the U.S. and has been approved as Suliqua^® in Europe and launched in the Netherlands.

ARIVA.DE Börsen-Geflüster

Kurse

Zealand Pharma

84,20 €

+2,62%

Zealand's clinical pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system to reduce the risk of hypoglycemia and better diabetes management (Phase 2) and other earlier-stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).

4-17_0602 Investor conferences

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zealand Pharma via Globenewswire

Mehr Nachrichten zur Zealand Pharma Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.